Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population.

Gupta, Alok; Hussain, Shaik Maheboob; Sonthwal, Neha; Chaturvedi, Harit

Gupta, Alok; Hussain, Shaik Maheboob; Sonthwal, Neha; Chaturvedi, Harit.

Affiliation

Gupta A; Department of Medical Oncology, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, India.
Hussain SM; Department of Medical Oncology, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, India.
Sonthwal N; Department of Clinical Research, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, India.
Chaturvedi H; Department of Surgical Oncology, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, India.

J Cancer Res Ther ; 17(2): 389-392, 2021.

Article de En | MEDLINE | ID: mdl-34121682

Sujet(s)
Mots clés

Abiraterone; docetaxel; metastatic hormone-sensitive prostate cancer

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la prostate / Protocoles de polychimiothérapie antinéoplasique / Docetaxel / Antagonistes des androgènes / Androstènes Type d'étude: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Humans / Male / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: J Cancer Res Ther Sujet du journal: NEOPLASIAS / TERAPEUTICA Année: 2021 Type de document: Article Pays d'affiliation: Inde Pays de publication: Inde

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google